Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 16;13(20):6164.
doi: 10.3390/jcm13206164.

The Potential Benefit of a Novel Urine Biosensor Platform for Lung Cancer Detection in the Decision-Making Process: From the Bench to the Bedside

Ory Wiesel  1 , Tatiyana Suharev  2 , Alaa Awad  1 , Lina Abzah  1 , Adi Laser-Azogui  2 , Michal Mark Danieli  2
Affiliations

The Potential Benefit of a Novel Urine Biosensor Platform for Lung Cancer Detection in the Decision-Making Process: From the Bench to the Bedside

Ory Wiesel et al. J Clin Med. .

Abstract

Background: Lung cancer is the leading cause of cancer-related mortality worldwide. Lung cancer screening and early detection resulted in a decrease in cancer-specific mortality; however, it introduced additional dilemmas and adherence barriers for patients and providers. Methods: Innovations such as biomolecular diagnosis and biosensor-based technology improve the detection and stratification of high-risk patients and might assist in overcoming adherence barriers, hence providing new horizons for better selection of screened populations. Conclusions: In the present manuscript, we discuss some of the dilemmas clinicians are currently facing during the diagnosis and treatment processes. We further highlight the potential benefits of a novel biosensor platform for lung cancer detection during the decision making process surrounding lung cancer.

Keywords: biomarkers; biosensors; biotechnology; cancer-diagnostics; early-detection; lung cancer; machine-learning; pulmonary; screening; volatile organic compounds.

PubMed Disclaimer

Conflict of interest statement

Authors T.S, A.L.-A. and M.M.D are employed by the company EARLY O.M. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A–D) Computed tomography and PET-CT scans of the presented patients. (A1) The arrow marks the suspicious cavitary lesion in the major fissure extending from the RLL to the RUL. (A2) The arrow marks the central hypermetabolic FDG avid nodule in the RLL. (B1) The arrow marks the apical mass in the vicinity of the emphysematous lung. (C1) The arrow marks the peripheral consolidation (on biopsy: chronic inflammation). (C2) The arrow marks the peripheral hypermetabolic FDG avid consolidation (on biopsy: chronic inflammation). (D1) The arrow marks a central hypermetabolic FDG avid nodule near the segmental pulmonary artery (biopsy was negative for tumor). (D2) The arrow marks central nodule (biopsy was negative for tumor).
See this image and copyright information in PMC

References

    1. National Lung Screening Trial Research Team. Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., Gareen I.F., Gatsonis C., Marcus P.M., et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N. Engl. J. Med. 2011;365:395–409. doi: 10.1056/NEJMoa1102873. - DOI - PMC - PubMed
    1. de Koning H.J., van der Aalst C.M., de Jong P.A., Scholten E.T., Nackaerts K., Heuvelmans M.A., Lammers J.-W.J., Weenink C., Yousaf-Khan U., Horeweg N., et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N. Engl. J. Med. 2020;382:503–513. doi: 10.1056/NEJMoa1911793. - DOI - PubMed
    1. Liu Y., Pan I.-W.E., Tak H.J., Vlahos I., Volk R., Shih Y.-C.T. Assessment of Uptake Appropriateness of Computed Tomography for Lung Cancer Screening According to Patients Meeting Eligibility Criteria of the US Preventive Services Task Force. JAMA Netw. Open. 2022;5:e2243163. doi: 10.1001/jamanetworkopen.2022.43163. - DOI - PMC - PubMed
    1. NCCN Guidelines for Patients: Lung Cancer Screening. 2023. [(accessed on 1 October 2024)]. Available online: https://www.nccn.org/patients/guidelines/content/PDF/lung_screening-pati....
    1. NCCN Lung Cacner Screening Guidelines V2.2024. [(accessed on 1 October 2024)]. Available online: https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1441.

LinkOut - more resources